Genentech Inc reports Phase III study of Avastin in advanced prostate cancer did not meet primary objective

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
GE Opens First New Manufacturing Operation in Louisville, Ky...
Get set for Bupa Great Birmingham Run...
New Regional Aircraft Contracts and Support...
Harris Corporation's John Shipley Honored by U.S...
Farmers can use red diesel to help out during extreme weather...
Hogan Lovells' It's Not Just Peanuts Campaign Wins Legal Business...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Genentech Inc reports Phase III study of Avastin in advanced prostate cancer did not meet primary objective
Biotechnology company Genentech Inc, part of the Roche Group (SIX:RO) (SIX:ROG) (OTCQX:RHHBY), said on Friday that a Phase III study of Avastin (bevacizumab) in men with late stage prostate cancer did not meet its primary objective of extending overall survival compared to chemotherapy and...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search